Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1.

J. Siliciano,R. Siliciano

DOI: https://doi.org/10.1016/j.jaci.2014.05.026

IF: 14.29

2014-07-01

Journal of Allergy and Clinical Immunology

Abstract:

What problem does this paper attempt to address?

Research progress on HIV latency-reversing agents and its mechanism

万智凯,朱彪

DOI: https://doi.org/10.3760/cma.j.issn.1674-2397.2021.06.011

2021-01-01

Abstract:Human immunodeficiency virus (HIV) infection causes severe systemic immune system damage and ultimately leads to patient death. Despite the success of anti-retroviral therapy (ART), which can effectively supress viral replication, there is currently no cure for HIV infection, which requires lifelong treatment. Due to the presence of HIV latent reservoir, the virus persists during antiretroviral treatment. "Shock and Kill" is currently one of the most recognized strategies for removing HIV latent reservoir. The solution is mainly to reactivate viral transcription by using latency-reversing agents (LRAs), which triggers cell lysis or immune-mediated clearance to kill the reactivated HIV infected cells and achieve functional cure. This article gives an overview of current research progress on HIV LRAs and their mechanism of action.
Recent progress on functional cure for acquired immunodeficiency syndrome

Jia Sun,Biao Zhu

DOI: https://doi.org/10.3760.cma.j.issn.1673-4149.2014.04.013

2014-01-01

Abstract:Acquired immunodeficiency syndrome caused by HIV has been considered as one of the worldwide incurable illnesses.Despite the huge clinical success of HAART,several factors such as adverse effects,requirement of life-long adherence,high cost,and drug resistance make the request for an ultimate cure of HIV/ AIDS.The functional cure is the achievement of spontaneous drug-free control of HIV infection without disease progression.The review summarizes the main achievements in protecting HIV target cells—CD4+ T cells,CLT immune enhancement,depletion of latent reservoir,hematopoietic stem cell transplantation and gene therapy.
Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Ruojing Bai,Shiyun Lv,Hao Wu,Lili Dai

DOI: https://doi.org/10.1155/2022/6952286

2022-05-31

Abstract:Since the first discovery of human immunodeficiency virus 1 (HIV-1) in 1983, the targeted treatment, antiretroviral therapy (ART), has effectively limited the detected plasma viremia below a very low level and the technique has been improved rapidly. However, due to the persistence of the latent reservoir of replication-competent HIV-1 in patients treated with ART, a sudden withdrawal of the drug inevitably results in HIV viral rebound and HIV progression. Therefore, more understanding of the HIV-1 latent reservoir (LR) is the priority before developing a cure that thoroughly eliminates the reservoir. HIV-1 spreads through both the release of cell-free particles and by cell-to-cell transmission. Mounting evidence indicates that cell-to-cell transmission is more efficient than cell-free transmission of particles and likely influences the pathogenesis of HIV-1 infection. This mode of viral transmission also influences the generation and maintenance of the latent reservoir, which represents the main obstacle for curing the infection. In this review, the definition, establishment, and maintenance of the HIV-1 LR, along with the state-of-the-art quantitative approaches that directly quantify HIV-1 intact proviruses, are elucidated. Strategies to cure HIV infection are highlighted. This review will renew hope for a better and more thorough cure of HIV infection for mankind and encourage more clinical trials to achieve ART-free HIV remission.
Research Progress on Human Immunodeficiency Virus Type 1 Latent Infection Activator

Peng Xiuming,Wu Nanping

DOI: https://doi.org/10.3760/cma.j.issn.1673-4149.2015.03.014

2015-01-01

Abstract:Highly active antiretroviral therapy (HAART) is effective in controlling HIV-1.However,due to the existence of viral reservoirs,HIV-1 can't be eliminated completely.The viral reservoir is established in the early stage of infection,possessing a very long half-life and staying quiescent most of the time,which is the major problem to the cure.Nowadays,the possible ways to eradicate HIV-1 are latent infection activator,immune-based therapies,gene therapy approaches and so on.The latent infection activator of HIV-1 is discussed in this article.
HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

Tessa C. Chou,Nishad S. Maggirwar,Matthew D. Marsden

DOI: https://doi.org/10.3390/v16071163

2024-07-20

Viruses

Abstract:The latent reservoir remains a major roadblock to curing human immunodeficiency virus (HIV) infection. Currently available antiretroviral therapy (ART) can suppress active HIV replication, reduce viral loads to undetectable levels, and halt disease progression. However, antiretroviral drugs are unable to target cells that are latently infected with HIV, which can seed viral rebound if ART is stopped. Consequently, a major focus of the field is to study the latent viral reservoir and develop safe and effective methods to eliminate it. Here, we provide an overview of the major mechanisms governing the establishment and maintenance of HIV latency, the key challenges posed by latent reservoirs, small animal models utilized to study HIV latency, and contemporary cure approaches. We also discuss ongoing efforts to apply these approaches in combination, with the goal of achieving a safe, effective, and scalable cure for HIV that can be extended to the tens of millions of people with HIV worldwide.

virology
Identify Potential Regulators in Hiv-1 Latency by Joint Microrna and Mrna Analysis

Zongxing Yang,Jin Yang,Juan Wang,Xiangyun Lu,Changzhong Jin,Tiansheng Xie,Nanping Wu

DOI: https://doi.org/10.1159/000430121

2015-01-01

Cellular Physiology and Biochemistry

Abstract:Background/Aims: The main obstacle to cure HIV infection is the existence of long-lasting latent reservoirs. Many efforts have been made to understand basal mechanisms of HIV-1 latency, in which miRNAs play an important role. However, integrated analysis of miRNA and mRNA expression in HIV-1 latency is lacking. Methods and Results: Global miRNA and mRNA expression was determined by microarrays and quantitative reverse transcription PCR in well-characterized HIV-1 latently and actively infected cells, respectively. Interactions of miRNA-mRNA, mRNA-mRNA, and transcription factor-miRNA pairs were assembled into the function network. Our results show that transcription regulation related genes were mostly enriched in HIV-1 latently infected cells. Gene set enrichment analysis revealed nuclear transport related pathways were up-regulated in the latency group. Network dynamic analysis highlighted many gene-pairs sharing the largest changes in different HIV-1 infection state. 83.33% miRNA-target pairs were validated against database, and RHOB related genes constitute the interface between HIV-1 latency and replication state. Conclusion: We show for the first time a joint miRNA and mRNA expression profile related to a HIV-1 latency phenotype, outline a dynamic network of potential regulators involving in HIV-1 latency or replication state, and gain new insights into the source messages for affecting HIV-1 latency.
The reservoir of latent HIV

Jing Chen,Tong Zhou,Yuan Zhang,Shumin Luo,Huan Chen,Dexi Chen,Chuanyun Li,Weihua Li

DOI: https://doi.org/10.3389/fcimb.2022.945956

IF: 6.073

2022-07-29

Frontiers in Cellular and Infection Microbiology

Abstract:The persistence of latent reservoir of the human immunodeficiency virus (HIV) is currently the major challenge in curing HIV infection. After HIV infects the human body, the latent HIV is unable to be recognized by the body's immune system. Currently, the widely adopted antiretroviral therapy (ART) is also unble to eliminate it, thus hindering the progress of HIV treatment. This review discusses the existence of latent HIV vault for HIV treatment, its formation and factors affecting its formation, cell, and tissue localization, methods for detection and removing latent reservoir, to provide a comprehensive understanding of latent HIV vault, in order to assist in the future research and play a potential role in achieving HIV treatment.

immunology,microbiology
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Christine Katlama,Steven G Deeks,Brigitte Autran,Javier Martinez-Picado,Jan van Lunzen,Christine Rouzioux,Michael Miller,Stefano Vella,Joern E Schmitz,Jeffrey Ahlers,Douglas D Richman,Rafick P Sekaly

DOI: https://doi.org/10.1016/S0140-6736(13)60104-X

2013-06-15

Abstract:Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Danielle E Lyons,Priti Kumar,Nadia R Roan,Patricia A Defechereux,Cedric Feschotte,Ulrike C Lange,Niren Murthy,Pauline Sameshima,Eric Verdin,Julie A Ake,Matthew S Parsons,Avindra Nath,Sara Gianella,Davey M Smith,Esper G Kallas,Thomas J Villa,Richard Strange,Betty Mwesigwa,Robert L Furler O'Brien,Douglas F Nixon,Lishomwa C Ndhlovu,Susana T Valente,Melanie Ott

DOI: https://doi.org/10.3390/v15112171

2023-10-28

Viruses

Abstract:Despite remarkable progress, a cure for HIV-1 infection remains elusive. Rebound competent latent and transcriptionally active reservoir cells persevere despite antiretroviral therapy and rekindle infection due to inefficient proviral silencing. We propose a novel "block-lock-stop" approach, entailing long term durable silencing of viral expression towards an irreversible transcriptionally inactive latent provirus to achieve long term antiretroviral free control of the virus. A graded transformation of remnant HIV-1 in PLWH from persistent into silent to permanently defective proviruses is proposed, emulating and accelerating the natural path that human endogenous retroviruses (HERVs) take over millions of years. This hypothesis was based on research into delineating the mechanisms of HIV-1 latency, lessons from latency reversing agents and advances of Tat inhibitors, as well as expertise in the biology of HERVs. Insights from elite controllers and the availability of advanced genome engineering technologies for the direct excision of remnant virus set the stage for a rapid path to an HIV-1 cure.
Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Marie Armani-Tourret,Benjamin Bone,Toong Seng Tan,Weiwei Sun,Maxime Bellefroid,Tine Struyve,Michael Louella,Xu G. Yu,Mathias Lichterfeld

DOI: https://doi.org/10.1038/s41579-024-01010-8

IF: 88.1

2024-02-11

Nature Reviews Microbiology

Abstract:Successful approaches for eradication or cure of HIV-1 infection are likely to include immunological mechanisms, but remarkably little is known about how human immune responses can recognize and interact with the few HIV-1-infected cells that harbour genome-intact viral DNA, persist long term despite antiretroviral therapy and represent the main barrier to a cure. For a long time regarded as being completely shielded from host immune responses due to viral latency, these cells do, on closer examination with single-cell analytic techniques, display discrete footprints of immune selection, implying that human immune responses may be able to effectively engage and target at least some of these cells. The failure to eliminate rebound-competent virally infected cells in the majority of persons likely reflects the evolution of a highly selected pool of reservoir cells that are effectively camouflaged from immune recognition or rely on sophisticated approaches for resisting immune-mediated killing. Understanding the fine-tuned interplay between host immune responses and viral reservoir cells will help to design improved interventions that exploit the immunological vulnerabilities of HIV-1 reservoir cells.

microbiology
Research progress on human immunodeficiency virus reservoir and its eradication

HE Yong-Quan,MENG Zhe-Feng,ZHANG Xiao-Yan

2012-01-01

Abstract:Highly active antiretroviral therapy(HAART) has driven human immunodeficiency virus(HIV) to undetectably low levels in the blood and improved life quality of HIV/acquired immunodeficiency syndrome(AIDS) patients.However,the eradication of HIV-1 is hindered by the persistence of long-lived,latently infected memory CD4 T cells and the formation of viral reservoirs.Research on HIV reservoir eradication mainly focus on gene therapy,drug treatment targeting latently HIV-1-infected cells or directly reactivating the latent viruses,which are easier to be killed by antiviral therapy.In this review,the recent research progress on HIV reservoir and its eradication is summarized.
Humanized mice for studying HIV latency and potentially its eradication

Moa F. Hasler,Roberto F. Speck,Nicole P. Kadzioch

DOI: https://doi.org/10.1097/coh.0000000000000855

2024-04-05

Current Opinion in HIV and AIDS

Abstract:The quest for an HIV cure faces a formidable challenge: the persistent presence of latent viral infections within the cells and tissues of infected individuals. This review provides a thorough examination of discussions surrounding HIV latency, the use of humanized mouse models, and strategies aimed at eliminating the latent HIV reservoir. It explores the hurdles and advancements in understanding HIV pathogenesis, mainly focusing on establishing latent reservoirs in CD4 + T cells and macrophages. Introducing the concepts of functional and sterile cures, the review underscores the indispensable role of humanized mouse models in HIV research, offering crucial insights into the efficacy of cART and the ongoing pursuit of an HIV cure.

immunology,infectious diseases
Latency reversal and viral clearance to cure HIV-1

David M Margolis,J Victor Garcia,Daria J Hazuda,Barton F Haynes,David M. Margolis,J. Victor Garcia,Daria J. Hazuda,Barton F. Haynes

DOI: https://doi.org/10.1126/science.aaf6517

IF: 56.9

2016-07-22

Science

Abstract:Next steps toward curing HIV-1 Since the discovery of HIV-1 more than 30 years ago, prevention and treatment strategies have dominated the research agenda. More recently, however, scientists are also focusing their efforts toward finding a cure. Margolis et al. review an approach that involves HIV-1 latency reversal and viral clearance. The idea is to reactivate any dormant virus and coax it to produce viral proteins that the immune system can recognize. By combining a latency reversal strategy with immunotherapies, the body might be able to rid itself of all infected cells. Science , this issue p. 362

multidisciplinary sciences
Post-Transcriptional HIV-1 Latency: A Promising Target for Therapy?

Kobayashi-Ishihara,Tsunetsugu-Yokota

DOI: https://doi.org/10.3390/v16050666

2024-04-25

Viruses

Abstract:Human Immunodeficiency Virus type 1 (HIV-1) latency represents a significant hurdle in finding a cure for HIV-1 infections, despite tireless research efforts. This challenge is partly attributed to the intricate nature of HIV-1 latency, wherein various host and viral factors participate in multiple physiological processes. While substantial progress has been made in discovering therapeutic targets for HIV-1 transcription, targets for the post-transcriptional regulation of HIV-1 infections have received less attention. However, cumulative evidence now suggests the pivotal contribution of post-transcriptional regulation to the viral latency in both in vitro models and infected individuals. In this review, we explore recent insights on post-transcriptional latency in HIV-1 and discuss the potential of its therapeutic targets, illustrating some host factors that restrict HIV-1 at the post-transcriptional level.

virology
Targeting Viral Transcription for HIV Cure Strategies

Jon Izquierdo-Pujol,Maria C. Puertas,Javier Martinez-Picado,Sara Morón-López

DOI: https://doi.org/10.3390/microorganisms12040752

IF: 4.5

2024-04-08

Microorganisms

Abstract:Combination antiretroviral therapy (ART) suppresses viral replication to undetectable levels, reduces mortality and morbidity, and improves the quality of life of people living with HIV (PWH). However, ART cannot cure HIV infection because it is unable to eliminate latently infected cells. HIV latency may be regulated by different HIV transcription mechanisms, such as blocks to initiation, elongation, and post-transcriptional processes. Several latency-reversing (LRA) and -promoting agents (LPA) have been investigated in clinical trials aiming to eliminate or reduce the HIV reservoir. However, none of these trials has shown a conclusive impact on the HIV reservoir. Here, we review the cellular and viral factors that regulate HIV-1 transcription, the potential pharmacological targets and genetic and epigenetic editing techniques that have been or might be evaluated to disrupt HIV-1 latency, the role of miRNA in post-transcriptional regulation of HIV-1, and the differences between the mechanisms regulating HIV-1 and HIV-2 expression.

microbiology
Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs

Amina Ait-Ammar,Anna Kula,Gilles Darcis,Roxane Verdikt,Stephane De Wit,Virginie Gautier,Patrick W. G. Mallon,Alessandro Marcello,Olivier Rohr,Carine Van Lint

DOI: https://doi.org/10.3389/fmicb.2019.03060

IF: 5.2

2020-01-24

Frontiers in Microbiology

Abstract:One of the most explored therapeutic approaches aimed at eradicating HIV-1 reservoirs is the "shock and kill" strategy which is based on HIV-1 reactivation in latently-infected cells ("shock" phase) while maintaining antiretroviral therapy (ART) in order to prevent spreading of the infection by the neosynthesized virus. This kind of strategy allows for the "kill" phase, during which latently-infected cells die from viral cytopathic effects or from host cytolytic effector mechanisms following viral reactivation. Several latency reversing agents (LRAs) with distinct mechanistic classes have been characterized to reactivate HIV-1 viral gene expression. Some LRAs have been tested in terms of their potential to purge latent HIV-1 <i>in vivo</i> in clinical trials, showing that reversing HIV-1 latency is possible. However, LRAs alone have failed to reduce the size of the viral reservoirs. Together with the inability of the immune system to clear the LRA-activated reservoirs and the lack of specificity of these LRAs, the heterogeneity of the reservoirs largely contributes to the limited success of clinical trials using LRAs. Indeed, HIV-1 latency is established in numerous cell types that are characterized by distinct phenotypes and metabolic properties, and these are influenced by patient history. Hence, the silencing mechanisms of HIV-1 gene expression in these cellular and tissue reservoirs need to be better understood to rationally improve this cure strategy and hopefully reach clinical success.

microbiology
Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation

Yan-Kai Wang,Long Wei,Wei Hu,Pei-Xia Yu,Zhong Li,Hai-Peng Yu,Xun Li

DOI: https://doi.org/10.3390/molecules28010003

IF: 4.6

2022-12-21

Molecules

Abstract:The existence of latent viral reservoirs (LVRs), also called latent cells, has long been an acknowledged stubborn hurdle for effective treatment of HIV-1/AIDS. This stable and heterogeneous reservoir, which mainly exists in resting memory CD4+ T cells, is not only resistant to highly active antiretroviral therapy (HAART) but cannot be detected by the immune system, leading to rapid drug resistance and viral rebound once antiviral treatment is interrupted. Accordingly, various functional cure strategies have been proposed to combat this barrier, among which one of the widely accepted and utilized protocols is the so-called 'shock-and-kill' regimen. The protocol begins with latency-reversing agents (LRAs), either alone or in combination, to reactivate the latent HIV-1 proviruses, then eliminates them by viral cytopathic mechanisms (e.g., currently available antiviral drugs) or by the immune killing function of the immune system (e.g., NK and CD8+ T cells). In this review, we focuse on the currently explored small molecular LRAs, with emphasis on their mechanism-directed drug targets, binding modes and structure-relationship activity (SAR) profiles, aiming to provide safer and more effective remedies for treating HIV-1 infection.

chemistry, multidisciplinary,biochemistry & molecular biology
Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

Hongtao Shang,Jiwei Ding,Shufei Yu,Tao Wu,Qiuli Zhang,Fujun Liang

DOI: https://doi.org/10.1038/aps.2015.22

IF: 7.169

2015-01-01

Acta Pharmacologica Sinica

Abstract:Highly active antiretroviral therapy (HAART) can effectively suppress the replication of human immunodeficiency virus-1 (HIV-1) and block disease progression. However, chronic HIV-1 infection remains incurable due to the persistence of a viral reservoir, including the transcriptionally silent provirus in CD4(+) memory T cells and the sanctuary sites that are inaccessible to drugs. Reactivation and the subsequent elimination of latent virus through virus-specific cytotoxic effects or host immune responses are critical strategies for combating the disease. Indeed, a number of latency reactivating reagents have been identified through mechanism-directed approaches and large-scale screening, including: (1) histone deacetylase inhibitors (HDACi); (2) cytokines and chemokines; (3) DNA methyltransferase inhibitors (DNMTI); (4) histone methyltransferase inhibitors (HMTI); (5) protein kinase C (PKC) activators; (6) P-TEFb activators; and (7) unclassified agents, such as disulfram. They have proved to be efficacious in latent cell line models and CD4(+) T lymphocytes from HIV-1-infected patients. This review comprehensively summarizes the recent progress and relative challenges in this field.
HIV-1 functional cure: will the dream come true?

Chao Liu,Xiancai Ma,Bingfeng Liu,Cancan Chen,Hui Zhang

DOI: https://doi.org/10.1186/s12916-015-0517-y

IF: 9.3

2015-11-20

BMC Medicine

Abstract:The reservoir of human immunodeficiency virus type 1 (HIV-1), a long-lived pool of latently infected cells harboring replication-competent viruses, is the major obstacle to curing acquired immune deficiency syndrome (AIDS). Although the combination antiretroviral therapy (cART) can successfully suppress HIV-1 viremia and significantly delay the progression of the disease, it cannot eliminate the viral reservoir and the patient must continue to take anti-viral medicines for life. Currently, the appearance of the ‘Berlin patient’, the ‘Boston patients’, and the ‘Mississippi baby’ have inspired many therapeutic strategies for HIV-1 aimed at curing efforts. However, the specific eradication of viral latency and the recovery and optimization of the HIV-1-specific immune surveillance are major challenges to achieving such a cure. Here, we summarize recent studies addressing the mechanisms underlying the viral latency and define two categories of viral reservoir: ‘shallow’ and ‘deep’. We also present the current strategies and recent advances in the development of a functional cure for HIV-1, focusing on full/partial replacement of the immune system, ‘shock and kill’, and ‘permanent silencing’ approaches.

medicine, general & internal
A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?

Ana Luiza Abdalla,Gabriel Guajardo-Contreras,Andrew J. Mouland

DOI: https://doi.org/10.3390/v16020229

2024-02-02

Viruses

Abstract:Worldwide, almost 40 million people are currently living with HIV-1. The implementation of cART inhibits HIV-1 replication and reduces viremia but fails to eliminate HIV-1 from latently infected cells. These cells are considered viral reservoirs from which HIV-1 rebounds if cART is interrupted. Several efforts have been made to identify these cells and their niches. There has been little success in diminishing the pool of latently infected cells, underscoring the urgency to continue efforts to fully understand how HIV-1 establishes and maintains a latent state. Reactivating HIV-1 expression in these cells using latency-reversing agents (LRAs) has been successful, but only in vitro. This review aims to provide a broad view of HIV-1 latency, highlighting Canadian contributions toward these aims. We will summarize the research efforts conducted in Canadian labs to understand the establishment of latently infected cells and how this informs curative strategies, by reviewing how HIV latency is established, which cells are latently infected, what methodologies have been developed to characterize them, how new compounds are discovered and evaluated as potential LRAs, and what clinical trials aim to reverse latency in people living with HIV (PLWH).

virology

Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1.

Research progress on HIV latency-reversing agents and its mechanism

Recent progress on functional cure for acquired immunodeficiency syndrome

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Research Progress on Human Immunodeficiency Virus Type 1 Latent Infection Activator

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

Identify Potential Regulators in Hiv-1 Latency by Joint Microrna and Mrna Analysis

The reservoir of latent HIV

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Research progress on human immunodeficiency virus reservoir and its eradication

Humanized mice for studying HIV latency and potentially its eradication

Latency reversal and viral clearance to cure HIV-1

Post-Transcriptional HIV-1 Latency: A Promising Target for Therapy?

Targeting Viral Transcription for HIV Cure Strategies

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs

Medicinal Chemistry of Anti-HIV-1 Latency Chemotherapeutics: Biotargets, Binding Modes and Structure-Activity Relationship Investigation

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

HIV-1 functional cure: will the dream come true?

A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?